Is it too late for Biogen?
World of DTC Marketing
FEBRUARY 2, 2022
Biogen will partner with Roche on the development, and potential sale of a promising cancer drug the Swiss pharma is advancing for several types of lymphoma, announcing Tuesday it’s exercised an option to share rights to the treatment. But is it too late for Biogen to stage a comeback with their reputation damaged? Biogen executives vowed to fight hard to reverse Medicare’s preliminary decision to sharply limit coverage of the company’s Alzheimer’s drug while saying more
Let's personalize your content